Atypical hemolytic uremic syndrome is a rare condition that can cause abnormal blood clotting in small blood vessels, destruction of red blood cells, and reduced platelet levels. Diagnosis can be challenging because its symptoms may overlap with other forms of hemolytic uremic syndrome and related disorders.
Atypical hemolytic uremic syndrome is a rare disorder associated with uncontrolled activation of the complement system, which is part of the immune system. The condition can affect small blood vessels and may lead to microangiopathic hemolytic anemia, low platelet levels, and kidney problems. Because these findings can occur in several medical conditions, diagnosis usually involves combining clinical findings with laboratory investigations rather than relying on a single test.
Doctors generally begin by reviewing symptoms, medical history, recent infections, medications, pregnancy-related factors, family history, and other possible causes of thrombotic microangiopathy. A physical examination may also help identify signs associated with anemia, reduced kidney function, or fluid retention.
Laboratory testing may include:
Complete blood count: Helps identify reduced platelet levels and anemia.
Blood smear: May show fragmented red blood cells called schistocytes, which can indicate microangiopathic hemolytic anemia.
Kidney function tests: Creatinine and other measurements help evaluate kidney involvement.
Hemolysis testing: Tests such as lactate dehydrogenase, bilirubin, and haptoglobin can provide evidence of red blood cell destruction.
Urine testing: Can identify blood or protein in the urine and provide information about kidney damage.
ADAMTS13 testing: May help distinguish atypical hemolytic uremic syndrome from thrombotic thrombocytopenic purpura, another form of thrombotic microangiopathy.
The diagnosis is based on the overall clinical picture and exclusion of other potential explanations.
Further testing may be considered when initial findings suggest a complement-mediated disorder. Complement-related investigations can provide additional information about abnormalities involving the complement system. Genetic testing may also be considered because changes in certain complement-related genes can increase susceptibility to atypical hemolytic uremic syndrome.
However, genetic testing does not identify every person with the condition. Some individuals may have no detectable genetic variant even when their clinical findings are consistent with the disorder. Similarly, complement test results can vary and may not independently confirm or exclude the diagnosis.
Additional assessments may include:
Complement protein and antibody testing when clinically appropriate.
Genetic analysis of genes associated with complement regulation.
Tests to investigate infections or other potential triggers.
Evaluation for medication-related or pregnancy-associated thrombotic microangiopathy.
Kidney imaging or other investigations when required to assess organ involvement.
Kidney biopsy in selected situations when the diagnosis remains uncertain or additional information is needed.
Early recognition of the condition can be important because kidney and other organ complications may develop rapidly in some people. Doctors may therefore begin evaluating possible causes while laboratory testing is still underway.
diagnosing atypical hemolytic uremic syndrome generally requires a combination of clinical assessment, blood and urine tests, kidney function evaluation, and investigations that help exclude other thrombotic microangiopathies. Complement testing and genetic analysis may provide additional information but are interpreted alongside other findings. Because the disorder can resemble several other conditions, diagnosis is typically made through a comprehensive evaluation by qualified healthcare professionals. This information is provided for educational purposes only and does not constitute medical advice, diagnosis, or treatment.